Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Electron transfer-based combination therapy of cisplatin with tetramethyl-p-phenylenediamine for ovarian, cervical, and lung cancers.

Luo T, Yu J, Nguyen J, Wang CR, Bristow RG, Jaffray DA, Zhou XZ, Lu KP, Lu QB.

Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10175-80. doi: 10.1073/pnas.1203451109. Epub 2012 Jun 8.

PMID:
22685209
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.

Judson PL, Watson JM, Gehrig PA, Fowler WC Jr, Haskill JS.

Cancer Res. 1999 May 15;59(10):2425-32.

PMID:
10344753
[PubMed - indexed for MEDLINE]
Free Article
3.

Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.

Yang YI, Kim JH, Lee KT, Choi JH.

Gynecol Oncol. 2011 Dec;123(3):588-96. doi: 10.1016/j.ygyno.2011.08.031. Epub 2011 Sep 25.

PMID:
21945308
[PubMed - indexed for MEDLINE]
4.

Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitive and -resistant gynecological cancer cell lines.

Du YH, Ho PC.

Cancer Chemother Pharmacol. 2001 Jun;47(6):481-90.

PMID:
11459200
[PubMed - indexed for MEDLINE]
5.

Combinatorial treatment of ovarian cancer cells with harringtonine and cisplatin results in increased cisplatin-DNA adducts.

Yunmbam MK, Guo Y, Miller MR, Yu JJ.

Oncol Rep. 2004 Apr;11(4):833-8.

PMID:
15010881
[PubMed - indexed for MEDLINE]
6.

A systematic overview of chemotherapy effects in ovarian cancer.

Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):340-60. Review.

PMID:
11441940
[PubMed - indexed for MEDLINE]
7.

Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.

van Moorsel CJ, Pinedo HM, Veerman G, Bergman AM, Kuiper CM, Vermorken JB, van der Vijgh WJ, Peters GJ.

Br J Cancer. 1999 Jun;80(7):981-90.

PMID:
10362105
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo.

Bardella C, Dettori D, Olivero M, Coltella N, Mazzone M, Di Renzo MF.

Clin Cancer Res. 2007 Apr 1;13(7):2191-8.

PMID:
17404103
[PubMed - indexed for MEDLINE]
Free Article
9.

Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines.

Kelland LR, Kimbell R, Hardcastle A, Aherne GW, Jackman AL.

Eur J Cancer. 1995 Jun;31A(6):981-6.

PMID:
7646933
[PubMed - indexed for MEDLINE]
10.

Alpha-TEA plus cisplatin reduces human cisplatin-resistant ovarian cancer cell tumor burden and metastasis.

Anderson K, Lawson KA, Simmons-Menchaca M, Sun L, Sanders BG, Kline K.

Exp Biol Med (Maywood). 2004 Dec;229(11):1169-76.

PMID:
15564444
[PubMed - indexed for MEDLINE]
11.

The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.

Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ.

Gynecol Oncol. 2004 Jul;94(1):67-73.

PMID:
15262121
[PubMed - indexed for MEDLINE]
12.

Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.

Tsunetoh S, Terai Y, Sasaki H, Tanabe A, Tanaka Y, Sekijima T, Fujioka S, Kawaguchi H, Kanemura M, Yamashita Y, Ohmichi M.

Cancer Biol Ther. 2010 Dec 1;10(11):1137-46. doi: 10.4161/cbt.10.11.13443. Epub 2010 Dec 1.

PMID:
20935474
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

PK11195 enhances chemosensitivity to cisplatin and paclitaxel in human endometrial and ovarian cancer cells.

Takai N, Ueda T, Nishida M, Nasu K, Narahara H.

Int J Mol Med. 2010 Jan;25(1):97-103.

PMID:
19956907
[PubMed - indexed for MEDLINE]
14.

Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers.

Wiseman LR, Spencer CM.

Drugs Aging. 1998 Apr;12(4):305-34. Review.

PMID:
9571394
[PubMed - indexed for MEDLINE]
15.

Wogonin potentiates cisplatin-induced cancer cell apoptosis through accumulation of intracellular reactive oxygen species.

He F, Wang Q, Zheng XL, Yan JQ, Yang L, Sun H, Hu LN, Lin Y, Wang X.

Oncol Rep. 2012 Aug;28(2):601-5. doi: 10.3892/or.2012.1841. Epub 2012 May 31.

PMID:
22665077
[PubMed - indexed for MEDLINE]
16.

β-Elemene promotes cisplatin-induced cell death in human bladder cancer and other carcinomas.

Li QQ, Wang G, Liang H, Li JM, Huang F, Agarwal PK, Zhong Y, Reed E.

Anticancer Res. 2013 Apr;33(4):1421-8.

PMID:
23564782
[PubMed - indexed for MEDLINE]
17.

Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.

Horváth V, Blanárová O, Svihálková-Sindlerová L, Soucek K, Hofmanová J, Sova P, Kroutil A, Fedorocko P, Kozubík A.

Gynecol Oncol. 2006 Jul;102(1):32-40. Epub 2005 Dec 20.

PMID:
16364413
[PubMed - indexed for MEDLINE]
18.

Synergistic anticancer activity of Thiazolo[5,4-b]quinoline derivative D3CLP in combination with cisplatin in human cervical cancer cells.

González-Sánchez I, Lira-Rocha A, Navarrete A, Loza-Mejía MA, Coronel-Cruz C, Mendoza-Rodríguez CA, Cerbón MA.

Anticancer Res. 2012 Dec;32(12):5159-65.

PMID:
23225412
[PubMed - indexed for MEDLINE]
19.

Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers.

Muggia FM.

Semin Oncol. 2004 Dec;31(6 Suppl 14):17-24. Review.

PMID:
15726530
[PubMed - indexed for MEDLINE]
20.

Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase.

Deng HB, Adikari M, Parekh HK, Simpkins H.

Cancer Chemother Pharmacol. 2004 Oct;54(4):301-7. Epub 2004 May 11.

PMID:
15138708
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk